Oregon Clinical Trials Report — June 2026

For Oregon residents considering participation in clinical trials, June 2026 presents a critical window of opportunity, particularly for those looking to enroll in studies that are nearing their conclusion. Across the state, 60 clinical trials are scheduled to close within the next 90 days, meaning interested individuals should act swiftly to explore these options before enrollment periods end. This urgent call to action includes 6 studies that are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Beyond these closing opportunities, Oregon's clinical research landscape remains vibrant, with 1,157 clinical trials currently recruiting across 35 cities and 515 research sites. This month, 12 new trials opened their doors to participants, a slight decrease from the 14 new studies launched in May 2026, but still offering fresh avenues for engagement in groundbreaking research.

Groundbreaking Research in Weight Management and Migraine Treatment

June brings several significant new Phase 3 drug trials to Oregon, spearheaded by major pharmaceutical sponsors. These studies are investigating potential new treatments for widespread health challenges, including obesity, overweight, and migraine, offering participants access to cutting-edge therapies.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654361, a Phase 3 study titled "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This substantial global trial aims to enroll 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily, in combination with a reduced-calorie diet.
• Another pivotal Phase 3 trial from Gasherbrum Bio, Inc. is NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This randomized, double-blind, placebo-controlled study will assess the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in 1,100 participants living with overweight or obesity and Type 2 Diabetes Mellitus (T2DM) over 76 weeks of treatment.
• For individuals experiencing migraines, Kallyope Inc. is leading two important Phase 3 studies. NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," is a double-blind, randomized, multicenter trial seeking 1,800 participants to compare elismetrep with placebo for acute migraine treatment.
• Complementing this, Kallyope Inc. is also sponsoring NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine." This study plans to enroll 1,000 participants to evaluate the safety and tolerability of intermittent use of elismetrep for acute migraine attacks over an extended period.
• In the realm of public health, Montefiore Medical Center is sponsoring NCT07631598, "Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses." This study, involving 512 participants, is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) can improve engagement and retention in treatment for opioid use disorder (OUD) compared to traditional referrals.

New Opportunities for Diverse Health Conditions

The 12 new trials opening in Oregon this month address a range of health conditions, with a notable focus on metabolic health and pain management. The most frequently targeted conditions in these new studies include:

• Chronic weight management (2 trials)
• Overweight (2 trials)
• Obesity (2 trials)
• Head and neck cancer (1 trial)
• Hearing loss (1 trial)
• Malignant head and neck neoplasm (1 trial)
• Melanoma (1 trial)
• Migraine (1 trial)
• Opioid use disorder (1 trial)
• Opioid use disorder, moderate (1 trial)

In terms of intervention types, the new research includes 4 drug trials, 3 behavioral studies, 1 device trial, and 6 other types of interventions, indicating a broad approach to medical advancement.

Time is Running Out for These Studies

For those living with specific health conditions, several trials are closing soon, making immediate action crucial. Conditions with trials nearing their enrollment deadlines include:

• Ovarian cancer (3 trials)
• Tricuspid regurgitation (2 trials)
• Duchenne muscular dystrophy (2 trials)
• Endometrial cancer (2 trials)
• Prostate cancer (2 trials)
• Fallopian tube cancer (2 trials)
• Advanced breast cancer (2 trials)
• Breast cancer (2 trials)
• Antiphospholipid syndrome (APS) (1 trial)
• Atopic dermatitis (1 trial)

If you or someone you know has one of these conditions, exploring these opportunities now could be vital.

Geographic Accessibility Across Oregon

Oregon's clinical research efforts are primarily concentrated in its largest urban center, but opportunities are available beyond the metropolitan hub. Of the 12 new trials this month, the vast majority, 11, are located in Portland. This reinforces Portland's role as a central hub for medical innovation and research in the state. However, access to new research is also expanding to other areas, with 1 new trial opening in Grants Pass, demonstrating a commitment to broader geographic reach for clinical investigations.

Participation for Healthy Volunteers and Diverse Demographics

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical science. Of the 12 new trials launched this month, 4 are actively seeking healthy volunteers. Statewide, a total of 100 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and advancing public health.

Clinical trials in Oregon are designed to be inclusive, with a broad range of eligibility criteria. Notably, all 12 of the new trials include older adults as potential participants, ensuring that research benefits this important demographic. There are no new trials exclusively for children, females, or males this month.

Academic institutions and industry sponsors both play significant roles in Oregon's research landscape. The OHSU Knight Cancer Institute is a prominent academic sponsor, leading 3 of the new trials. Industry sponsors like Gasherbrum Bio, Inc. and Kallyope Inc. are driving significant drug development efforts, sponsoring 2 trials each. Overall, 5 new trials are industry-sponsored, 1 is federally funded, and 6 fall under other sponsorship categories, including academic institutions.

As we move through June, Oregon's commitment to advancing medical knowledge remains strong, with a focus on both urgent enrollment needs and the launch of promising new studies across a spectrum of health challenges.